| 34.925 0.185 (0.53%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.36  |
1-year : | 48.31 |
| Resists | First : | 35.41 |
Second : | 41.36 |
| Pivot price | 28.08 |
|||
| Supports | First : | 27.18 |
Second : | 22.1 |
| MAs | MA(5) : | 33.93 |
MA(20) : | 26.74 |
| MA(100) : | 21.82 |
MA(250) : | 22.74 |
|
| MACD | MACD : | 2.9 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 94.4 |
D(3) : | 93.4  |
| RSI | RSI(14): 84.5 |
|||
| 52-week | High : | 35.41 | Low : | 14.59 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CSTL ] has closed below upper band by 13.1%. Bollinger Bands are 277.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 34.85 - 35.02 | 35.02 - 35.19 |
| Low: | 32.12 - 32.29 | 32.29 - 32.47 |
| Close: | 34.45 - 34.74 | 34.74 - 35.02 |
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Tue, 11 Nov 2025
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Tue, 11 Nov 2025
Is Castle Biosciences Ready To Turn Stability Into Growth? - RTTNews
Tue, 11 Nov 2025
4 Stocks With Recent Price Strength to Enhance Your Portfolio - TradingView
Fri, 07 Nov 2025
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,695 Shares of Stock - MarketBeat
Fri, 07 Nov 2025
Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,678 Shares - MarketBeat
Thu, 06 Nov 2025
Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 29 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 93.5 (%) |
| Shares Short | 1,610 (K) |
| Shares Short P.Month | 1,800 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 15.71 |
| Profit Margin | -2.8 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | -2.8 % |
| Return on Equity (ttm) | -2.2 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 9.66 |
| Sales Per Share | 11.93 |
| EBITDA (p.s.) | 0.67 |
| Qtrly Earnings Growth | -51.6 % |
| Operating Cash Flow | 62 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | -102.36 |
| PEG Ratio | 0 |
| Price to Book value | 2.21 |
| Price to Sales | 2.91 |
| Price to Cash Flow | 16.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|